Using MRI to detect placenta adhesion issues in pregnant women
MRI Screening of Placenta Adhesion Abnormalities
This study is testing if a special type of MRI can better spot placenta problems in pregnant women who are at risk, without using any contrast agents for safety.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 71 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Trial ID | NCT04328532 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of quantitative MRI techniques in diagnosing Placenta Adhesion Abnormalities (PAA) in pregnant women between 30 and 38 weeks of gestation. By measuring specific MRI parameters related to placental perfusion and oxygenation, the study seeks to improve the detection rates of PAA compared to standard ultrasound methods. The research will involve participants who are at risk for PAA, such as those with low-lying or covering placentas. The MRI will be performed without the use of gadolinium-based contrast agents to ensure safety for the mother and fetus.
Who should consider this trial
Good fit: Ideal candidates for this study are pregnant women aged 18 and older, between 30 and 38 weeks of gestation, who are at risk for PAA and plan to give birth at the CHRU of Nancy.
Not a fit: Patients with multiple pregnancies or those who have contraindications to MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of placenta adhesion abnormalities, potentially reducing severe maternal complications during delivery.
How similar studies have performed: While MRI has been used in similar contexts, the specific application of quantitative MRI for PAA detection is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant participant between 30 and 38 weeks of gestation, * Age ≥18 years old, * Participant who completed the preliminary medical examination, * Participant who has received full information about the organization of the research and has signed her informed consent. * Participant planning to give birth at CHRU of Nancy * Participant presenting risk factors for PAA : low-lying or covering placenta or in front of the uterine scar. Exclusion Criteria: * Multiple pregnancy, * Participant presenting at least one contraindication or restriction to performing an MRI as described in the protocol, in accordance with the current recommendations, * Participant unable to understand or follow study procedure, * Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the Public Health Code.
Where this trial is running
Vandœuvre-lès-Nancy
- Centre Hospitalier Régional Universitaire de Nancy — Vandœuvre-lès-Nancy, France (Recruiting)
Study contacts
- Study coordinator: Charline BERTHOLDT, MI
- Email: c.bertholdt@chru-nancy.fr
- Phone: +33 3 83 34 43 12
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.